secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0000879407-25-000004
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead licenses ARO-SNCA to Novartis for $200M upfront, up to $2B milestones
-------------------------------------------------------------------------------

- Arrowhead receives $200M upfront; eligible for up to $2B in development, regulatory, sales milestones.
- Novartis gets exclusive worldwide license to preclinical ARO-SNCA (siRNA for synucleinopathies like Parkinson's).
- Arrowhead will complete preclinical work; Novartis handles clinical development, manufacturing, commercialization.
- Arrowhead eligible for tiered royalties up to low double digits on net product sales.
- Transaction expected to close H2 2025, subject to HSR antitrust clearance and customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000087940725000004/0000879407-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000087940725000004/arwr-20250902.htm
  HTML page:      https://secwatch.observer/filing/0000879407-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer